دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Aims+Scope/Editorial Board/Publication information
doi : 10.1016/S0167-8140(23)00242-6
Volume 183, June 2023, 109704
First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer
Michael J. Dubec a,b,⇑, David L. Buckley b,c , Michael Berks a , Abigael Clough d , John Gaffney e , Anubhav Datta a,f , Damien J. McHugh a,b , Nuria Porta g , Ross A. Little a , Susan Cheung a , Christina Hague e , Cynthia L. Eccles a,d , Peter J. Hoskin a,h , Robert G. Bristow a,e , Julian C. Matthews i , Marcel van Herk a , Ananya Choudhury a,e , Geoff J.M. Parker j,k , Andrew McPartlin e,l , James P.B. O’Connor
doi : 10.1016/j.radonc.2023.109592
Volume 183, June 2023, 109592
First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer
Treatment of oropharyngeal squamous cell carcinoma: Is swallowing quality better after TORS or RT?
Flaminia Campo a,b,⇑, Oreste Iocca c , Armando De Virgilio d,e , Francesco Mazzola a , Giuseppe Mercante d,e , Barbara Pichi a , Floyd Christopher Holsinger f , Pasquale Di Maio g , Sara Ramella h , Raul Pellini
doi : 10.1016/j.radonc.2023.109547
Volume 183, June 2023, 109547
To answer an important question regarding the long-term morbidity of two oncological equivalent treatment for oropharyngeal squamous cell carcinoma (OPSCC), namely a comparison of swallowing function results between patients treated with trans-oral robotic surgery (TORS) versus patients treated with radiotherapy (RT).
Outcome prediction models incorporating clinical variables for Head and Neck Squamous cell Carcinoma: A systematic review of methodological conduct and risk of bias
Farhannah Aly a,b,c,⇑, Christian Rønn Hansen d,e,f,g , Daniel Al Mouiee a,b,c , Purnima Sundaresan h,i , Ali Haidar a,b , Shalini Vinod b,c,1 , Lois Holloway
doi : 10.1016/j.radonc.2023.109629
Volume 183, June 2023, 109629
Multiple outcome prediction models have been developed for Head and Neck Squamous Cell Carcinoma (HNSCC). This systematic review aimed to identify HNSCC outcome prediction model studies, assess their methodological quality and identify those with potential utility for clinical practice.
Can quantitative parameters of spectral computed tomography predict lymphatic metastasis in lung cancer? a systematic review and meta-analysis
Tong Wang a , Zheng Fan b , Lue Zou a , Yang Hou
doi : 10.1016/j.radonc.2023.109643
Volume 183, June 2023, 109643
This study evaluated the use of quantitative spectral computed tomography (CT) parameters to identify lymph node metastasis (LM) in lung cancer.
A systematic literature review of definitions and classification systems for radiotherapy innovation: A first step towards building a value-based assessment tool for radiation oncology
Miet Vandemaele a,⇑, Marianne Aznar b , Pierre Blanchard c , Josep M Borras d , Michelle Leech e , Ajay Aggarwal f,g,1 , Yolande Lievens
doi : 10.1016/j.radonc.2023.109602
Volume 183, June 2023, 109602
Timely access to radiotherapy innovations remains suboptimal, partly because there is no commonly agreed appraisal system suitable for the broad range of radiotherapy interventions. The Health Economics in Radiation Oncology (HERO) programme of ESTRO therefore engaged in building a radiotherapy-specific value-based framework.
The value of postoperative radiotherapy in thymoma patients with myasthenia gravis
Liu Chen a , Yi Li b , Xiaohua Dong b , Guilong Tanzhu a , Xianjing Chu a , Fuxing Deng a , Xiang Li c , Jing Zhang a , Bin Long d , Di Jing a , Lishui Niu a , Haiqin Peng a , Huan Yang b,1 , Rongrong Zhou
doi : 10.1016/j.radonc.2023.109644
Volume 183, June 2023, 109644
Surgery is the first-line treatment for patients with thymoma associated with myasthenia gravis (MG); however, the value of radiotherapy among these patients remains debatable. Herein, we examined the impact of postoperative radiotherapy (PORT) on the efficacy and prognosis of patients with thymoma and MG.
ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer
Nina-Sophie Schmidt-Hegemann a,1,2,⇑, Constantinos Zamboglou b,c,1 , Malcolm Mason d , Nicolas Mottet e , Karel Hinnen f , Gert De Meerleer g , Cesare Cozzarini h , Philippe Maingon i , Ann Henry j , Martin Spahn k , Philip Cornford l , Claus Belka a,m,2 , Thomas Wiegel
doi : 10.1016/j.radonc.2023.109544
Volume 183, June 2023, 109544
There is no consensus concerning the appropriate use of androgen deprivation therapy (ADT) during primary and postoperative external-beam radiotherapy (EBRT) in the management of prostate cancer (PCa). Thus, the European Society for Radiotherapy and Oncology (ESTRO) Advisory Committee for Radiation Oncology Practice (ACROP) guidelines seeks to present current recommendations for the clinical use of ADT in the various indications of EBRT.
Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease
Kewen He a,b , David S. Hong c , Chad Tang b , Duygu Sezen d , Livia Cox b , Aurian Maleki b,e , Genevieve Bertolet b , Quynh-Nhu Nguyen a , Nathan I. Comeaux b , Lily Schuda b , Dawei Chen a , James W. Welsh
doi : 10.1016/j.radonc.2023.109618
Volume 183, June 2023, 109618
Ipilimumab plus stereotactic ablative radiotherapy (SABR) demonstrate satisfactory short-term clinical benefit and low toxicities in metastatic cancers. Here, we report the 5-year overall survival (OS) rates for patients with metastatic disease treated with this combined-modality therapy in a phase II trial (NCT02239900).
Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 study
Haiyan Zeng a,⇑, Lizza E.L. Hendriks b , Willem J.A. Witlox c , Harry J.M. Groen d , Anne-Marie C. Dingemans e , John Praag f , José Belderbos g , Ruud Houben a , Vincent van der Noort h , Dirk K.M. De Ruysscher
doi : 10.1016/j.radonc.2023.109627
Volume 183, June 2023, 109627
To identify risk factors for self-reported cognitive impairment in radically treated stage III non-small cell lung cancer (NSCLC).
Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX – The LAPC-2 trial
Freek R. van ’t Land a , Diba Latifi a , Miranda Moskie a , Marjolein Y.V. Homs b , Koop Bosscha c , Bert A. Bonsing d , Sven D. Mieog d , Erwin van der Harst e , Peter-Paul L.O. Coene e , Jan H. Wijsman f , George P. van der Schelling f , Bas Groot Koerkamp a , Joost J. Nuyttens g , Casper H.J. van Eijck a,⇑, on behalf of the South West Pancreatic Cancer Care SWPCC consortium
doi : 10.1016/j.radonc.2023.109541
Volume 183, June 2023, 109541
In this phase I/II trial, non-progressive locally advanced pancreatic cancer (LAPC) patients after (modified)FOLFIRINOX therapy were treated with stereotactic body radiotherapy (SBRT) combined with heat-killed mycobacterium (IMM-101) vaccinations. We aimed to assess safety, feasibility, and efficacy of this treatment approach.
Voluntary versus mechanically-induced deep inspiration breath-hold for left breast cancer: A randomized controlled trial
Loïc Vander Veken a,b,⇑, Geneviève Van Ooteghem a,b , Ariane Razavi b , Sergio Da Rita Quaresma b , Eleonore Longton b , Carine Kirkove b , Benjamin Ledoux b , Ad Vandermeulen b , Christel Abdel Massih b , Pascale Henderickx b , Mortimer Gabriels b , Céline Delvaux b , Faycal Salah b , Aude Vaandering a,b , Xavier Geets
doi : 10.1016/j.radonc.2023.109598
Volume 183, June 2023, 109598
Deep inspiration breath-hold (DIBH) protects critical organs-at-risk (OARs) for adjuvant breast radiotherapy. Guidance systems e.g. surface guided radiation therapy (SGRT) improve the positional breast reproducibility and stability during DIBH.
Financial toxicity in cancer patients undergoing radiotherapy in a universal health care system – A prospective multicenter study of 1075 patients
Alexander Fabian a,⇑, Alexander Rühle b , Justus Domschikowski a , Maike Trommer c,d , Simone Wegen c , Jan-Niklas Becker e , Georg Wurschi f , Simon Boeke g , Mathias Sonnhoff h , Christoph A. Fink i , Lukas Käsmann j,k,l , Melanie Schneider m , Elodie Bockelmann n , Martin Treppner o , David Krug a , Nils H. Nicolay
doi : 10.1016/j.radonc.2023.109604
Volume 183, June 2023, 109604
To establish and confirm prevalence as well as risk factors of financial toxicity in a large national cohort of cancer patients undergoing radiotherapy in a universal health care system.
Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: Exploring the model-based approach
Loeki Aldenhoven a , B. Ramaekers a,⇑, J. Degens b , C. Oberije c , J. van Loon d , A.C. Dingemans e , D. De Ruysscher d , M. Joore
doi : 10.1016/j.radonc.2022.11.006
Volume 183, June 2023, 109417
Proton radiotherapy (PT) is a promising but more expensive strategy than photon radiotherapy (XRT) for the treatment of non-small cell lung cancer (NSCLC). PT is probably not cost-effective for all patients.
On the implant stability in adaptive multi-catheter breast brachytherapy: Establishment of a decision-tree for treatment re-planning
Andre Karius a,b,⇑, Juliane Szkitsak a,b , Vratislav Strnad a,b , Michael Lotter a,b , Stephan Kreppner a,b , Philipp Schubert a,b , Rainer Fietkau a,b , Christoph Bert
doi : 10.1016/j.radonc.2023.109597
Volume 183, June 2023, 109597
To assess implant stability and identify causes of implant variations during high-dose-rate multi-catheter breast brachytherapy.
Comparison of supraclavicular surgery plus radiotherapy versus radiotherapy alone in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis: A multicenter retrospective study
Yu-Chun Song a,1 , Jie Kong b,1 , Na Li c,1 , Xiao-Lei Liu a,d,1 , Xiao-Hong Li b , Long-Yu Zhu b , Yu-Wei Wang c , Hui Fang a , Hao Jing a , Yu Tang a , Ye-Xiong Li a,⇑, Xiao-Hong Wang c,⇑, Jun Zhang b,⇑, Shu-Lian Wang
doi : 10.1016/j.radonc.2023.109639
Volume 183, June 2023, 109639
To evaluate and compare the outcomes of supraclavicular lymph node dissection plus radiotherapy (RT) and RT alone for patients with synchronous ipsilateral supraclavicular lymph node metastasis.
Recurrence analysis of glioblastoma cases based on distance and dose information
Marco Langhans a,d,e,⇑,1 , Ilinca Popp a,b,1 , Anca L. Grosu a,b , Nadya Shusharina d , Harald Binder c , Dimos Baltas a,b , Thomas Bortfeld
doi : 10.1016/j.radonc.2023.109600
Volume 183, June 2023, 109600
Radiation therapy for glioblastoma (GBM) typically involves large target volumes. The aim of this study was to examine the recurrence pattern of GBM following modern radiochemotherapy according to EORTC guidelines and provide dose and distance information for the choice of optimal target volume margins.
Radiotherapy opens the blood–brain barrier and synergizes with anlotinib in treating glioblastoma
Pei-Jing Li a,b,1 , Shu-Zhen Lai c,1 , Ting Jin a , Hang-Jie Ying d , Ya-Mei Chen d , Peng Zhang a , Qing-Qing Hang a , Huan Deng a , Lei Wang a , Jian-Guo Feng d , Xiao-Zhong Chen a , Peng Guo e , Ming Chen f,⇑, Ye Tian b,⇑, Yuan-Yuan Chen f,
doi : 10.1016/j.radonc.2023.109633
Volume 183, June 2023, 109633
Glioblastoma (GBM) has a poor prognosis and lacks effective treatment. Anlotinib is a multitargeted receptor tyrosine kinase inhibitor (TKI) that may have anti-tumor activity in the central nervous system (CNS). This study aimed to determine the therapeutic value of radiotherapy combined with anlotinib in GBM via preclinical research.
Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?
Fatima Tensaouti a,b,⇑, Franck Desmoulin b , Julia Gilhodes c , Margaux Roques d,b , Soleakhena Ken e,l , Jean-Albert Lotterie b,f , Georges Noël g , Gilles Truc h , Marie-Pierre Sunyach i , Marie Charissoux j , Nicolas Magné k , Vincent Lubrano b , Patrice Péran b , Elizabeth Cohen-Jonathan Moyal a,l , Anne Laprie
doi : 10.1016/j.radonc.2023.109665
Volume 183, June 2023, 109665
All glioblastoma subtypes share the hallmark of aggressive invasion, meaning that it is crucial to identify their different components if we are to ensure effective treatment and improve survival.
Accurate tumor segmentation and treatment outcome prediction with DeepTOP
Lanlan Li a,1 , Bin Xu a,1 , Zhuokai Zhuang b,c,d,e,1 , Juan Li f,1 , Yihuang Hu a , Hui Yang g , Xiaolin Wang b,c , Jinxin Lin b,c,d,e , Ruwen Zhou h , Weiwei Chen i,j , Dongzhi Ran k,l , Meijin Huang b,c,d,e , Dabiao Wang m,⇑, Yanxin Luo b,c,d,e,⇑, Huichuan Yu
doi : 10.1016/j.radonc.2023.109550
Volume 183, June 2023, 109550
Accurate outcome prediction prior to treatment can facilitate trial design and clinical decision making to achieve better treatment outcome.
Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE
Véronique VENDRELY a,b,⇑, Claire LEMANSKI c , Pascal POMMIER d , Karine LE MALICOT e,f , Angélique SAINT g , Eleonor RIVIN DEL CAMPO h , Pauline REGNAULT i , Nabil BABA-HAMED j , Philippe RONCHIN k , Gilles CREHANGE l , David TOUGERON m , Elodie MENAGER-TABOUREL n , Olivia DIAZ o , Michael HUMMELSBERGER p , Mathieu MINSAT q , Franck DROUET r , Anne LARROUY s , Didier PEIFFERT t , Astrid LIEVRE u , Xavier ZASADNY v , Vincent HAUTEFEUILLE w , Françoise MORNEX x , Côme LEPAGE y , Laurent QUERO
doi : 10.1016/j.radonc.2023.109542
Volume 183, June 2023, 109542
International guidelines regarding the treatment of squamous cell carcinoma of the anus (SCCA) recommend intensity-modulated radiotherapy (IMRT) combined with mitomycin-based chemotherapy (CT). The French FFCD-ANABASE cohort aimed at evaluating clinical practices, treatment, and outcomes of SCCA patients.
Adjuvant radiotherapy in node-negative salivary malignancies of the parotid gland: A multi-institutional analysis
Jung Bin Park a,1 , Hong-Gyun Wu a , Jin Ho Kim a , Joo Ho Lee a , Soon-Hyun Ahn b , Eun-Jae Chung b , Keun-Yong Eom c , Woo-Jin Jeong d , Tack-Kyun Kwon e , Suzy Kim f , Chan Woo Wee
doi : 10.1016/j.radonc.2023.109554
Volume 183, June 2023, 109554
To determine the role of adjuvant radiotherapy (ART) in parotid gland cancer without nodal metastasis, we evaluated the survival outcomes, prognostic factors, and dose–response relationships in patients with node-negative parotid gland cancer patients.
Endonasopharyngeal ultrasound and magnetic resonance imaging features of recurrent retropharyngeal nodes in nasopharyngeal carcinoma patients: A radiologic-histopathologic study
Wencheng Tan a,g,1 , Minjie Mao b,g,1 , Haoqiang He c,g,1 , Mingshi Chen d,g,1 , Qiwen Deng e,1 , Youzhuo Yang a,g , Yin Li a,g , Hui Sheng f,g,⇑, Longjun He a,g,⇑, Jianjun Li
doi : 10.1016/j.radonc.2023.109579
Volume 183, June 2023, 109579
The imaging criteria of malignant retropharyngeal lymph node (RLN) in nasopharyngeal cancer (NPC) have yet to be fully elucidated. This study aimed to establish predictive models based on ultrasound (US) and magnetic resonance (MR) characteristics for identifying malignant RLN in NPC patients after radiotherapy.
Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation
Zheng Wu a,1 , Bin Qi b,1 , Fei-Fei Lin c,1 , Lin Zhang a , Qian He a , Fei-Ping Li d , Hui Wang a , Ya-Qian Han a,⇑, Wen-Jing Yin
doi : 10.1016/j.radonc.2023.109595
Volume 183, June 2023, 109595
To summarize the characteristics of local extension of eccentric and central nasopharyngeal carcinoma (NPC) by magnetic resonance imaging (MRI) and to improve clinical target volume (CTV) delineation.
Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma
Zi-Jian Lu a,b,1 , Ting Liu d,1 , Jie-Yi Lin a,c,1 , Sheng-Ting Pei a,b,1 , Ling Guo a,b,⇑, Sai-Lan Liu a,b,⇑, Hai-Qiang Mai
doi : 10.1016/j.radonc.2023.109635
Volume 183, June 2023, 109635
Radiomic feature repeatability and its impact on prognostic model generalizability: A multi-institutional study on nasopharyngeal carcinoma patients
Jiang Zhang a , Sai-Kit Lam b,c,1 , Xinzhi Teng a,1 , Zongrui Ma a,2 , Xinyang Han a,2 , Yuanpeng Zhang d,1 , Andy Lai-Yin Cheung g,2 , Tin-Ching Chau e,2 , Sherry Chor-Yi Ng e , Francis Kar-Ho Lee f,2 , Kwok-Hung Au f,2 , Celia Wai-Yi Yip f,2 , Victor Ho-Fun Lee g , Ying Han h , Jing Cai
doi : 10.1016/j.radonc.2023.109578
Volume 183, June 2023, 109578
To investigate the radiomic feature (RF) repeatability via perturbation and its impact on cross-institutional prognostic model generalizability in Nasopharyngeal Carcinoma (NPC) patients.
Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study
Joint Head and Neck Radiotherapy-MRI Development CooperativeAbdallah S.R. Mohamed a,c,1 , Abdelrahman Abusaif a,1 , Renjie He a,1 , Kareem A. Wahid a,c,1 , Vivian Salama a,c,1 , Sara Youssef a,1 , Brigid A. McDonald a,c,1 , Mohamed Naser a,1 , Yao Ding a,1 , Travis C. Salzillo a,1 , Moamen A. AboBakr a,1 , Jihong Wang a,1 , Stephen Y. Lai a,b,c,1,⇑, Clifton D. Fuller
doi : 10.1016/j.radonc.2023.109641
Volume 183, June 2023, 109641
To determine DWI parameters associated with tumor response and oncologic outcomes in head and neck (HNC) patients treated with radiotherapy (RT).
Prognostic radiomic signature for head and neck cancer: Development and validation on a multi-centric MRI dataset
Marco Bologna a,⇑, Valentina Corino a , Stefano Cavalieri b , Giuseppina Calareso c , Silvia Eleonora Gazzani d , Tito Poli e , Marco Ravanelli f , Davide Mattavelli g , Pim de Graaf h , Irene Nauta i , Kathrin Scheckenbach j , Lisa Licitra b,k , Luca Mainardi
doi : 10.1016/j.radonc.2023.109638
Volume 183, June 2023, 109638
Prognosis in locally advanced head and neck cancer (HNC) is currently based on TNM staging system and tumor subsite. However, quantitative imaging features (i.e., radiomic features) from magnetic resonance imaging (MRI) may provide additional prognostic info. The aim of this work is to develop and validate an MRI-based prognostic radiomic signature for locally advanced HNC.
Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09)
Tae Hoon Lee a,1 , Hyunju Shin b,1 , Yong Chan Ahn b , Min Kyu Kang c , Changhoon Song d , Woo Chul Kim e , Sung Ho Moon f , Jin Hee Kim g , Jaeho Cho h , Hae Jin Park i , Heui Kwan Lee j , Byoung Hyuck Kim k,l,⇑, Hak Jae Kim
doi : 10.1016/j.radonc.2023.109572
Volume 183, June 2023, 109572
To present the multi-institutional data on patterns of recurrence, treatment approaches, and clinical outcomes for regional lymph node (LN) recurrence after stereotactic body radiation therapy (SBRT) for primary lung cancer.
Biological equivalent dose is associated with radiological toxicity after lung stereotactic ablative radiation therapy
Carla Cases a , Mariana Benegas b,c , Marcelo Sánchez b,c , Ivan Vollmer b,c,d , Francesc Casas a,c , Carles Gomà a,e,⇑, Meritxell MollÃ
doi : 10.1016/j.radonc.2023.109552
Volume 183, June 2023, 109552
Stereotactic ablative radiation therapy (SABR) is the standard of care for inoperable early-stage non-small-cell lung cancer.
CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients
Chao Zhou a,1 , Liqiao Hou a,1 , Xingni Tang a,1 , Changxing Liu c , Yinnan Meng a , Haijian Jia d , Haihua Yang a,⇑, Suna Zhou
doi : 10.1016/j.radonc.2023.109637
Volume 183, June 2023, 109637
Although adaptive radiotherapy (ART) has many advantages, ART is not universal in the clinical appliance due to the consumption of a lot of labor, and economic burden. It is necessary to explore a CT stimulation-based radiomics model for screening who can get more benefits from ART in locally advanced non-small cell lung cancer (NSCLC) patients.
Clinical results of carbon ion radiotherapy for inoperable stage I non-small cell lung cancer: A Japanese national registry study (J-CROS-LUNG)
Nobuteru Kubo a,⇑, Hiroaki Suefuji b , Mio Nakajima c , Sunao Tokumaru d , Naoko Okano a , Daisaku Yoshida e , Osamu Suzuki f , Hitoshi Ishikawa c , Miyako Satouchi g , Haruhiko Nakayama h , Yoshiyuki Shioyama
doi : 10.1016/j.radonc.2023.109640
Volume 183, June 2023, 109640
Radiotherapy is a standard treatment for inoperable stage I non-small cell lung cancer (NSCLC), and carbon-ion radiation therapy (CIRT) may be used for such treatment. Although CIRT for stage I NSCLC has demonstrated favorable outcomes in previous reports, the reports covered only single-institution studies.
Local control correlates with overall survival in radiotherapy for early-stage non-small cell lung cancer: A systematic review
Naoko Sanuki a,b , Atsuya Takeda a,⇑, Takahisa Eriguchi a , Yuichiro Tsurugai a , Yudai Tateishi c , Yuichi Kibe d , Takeshi Akiba a,e , Tsuyoshi Fukuzawa a,f , Nobuyuki Horita
doi : 10.1016/j.radonc.2023.109664
Volume 183, June 2023, 109664
Local control (LC) is an important outcome of local cancer therapy, besides overall survival (OS). We conducted a comprehensive literature search to investigate whether a high LC rate contributes to good OS in radiotherapy for early-stage non-small cell lung cancer (ES-NSCLC).
Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease
Kenji Makita a,b,⇑, Yasushi Hamamoto a , Hiromitsu Kanzaki a , Kei Nagasaki a , Yoshifumi Sugawara c , Toshiyuki Kozuki
doi : 10.1016/j.radonc.2023.109636
Volume 183, June 2023, 109636
Acute exacerbations or acute lung injury, including radiation pneumonitis (AE-ALI/RP) of interstitial lung disease (ILD), has a fatal prognosis. We evaluated the risk of palliative-intent radiotherapy (RT), with or without lung irradiation, for AE-ALI/RP of ILD.
Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study
Amy de Haar-Holleman a,1 , Lisa M.C. van Hoogstraten b,c,⇑,1 , Maarten C.C.M. Hulshof d , Metin Tascilar e , Katharina Brück b,d , BlaZIB study group, Richard P. Meijer f , J. Alfred Witjes f , Lambertus A. Kiemeney c,g , Katja K.H. Aben
doi : 10.1016/j.radonc.2023.109584
Volume 183, June 2023, 109584
Oral capecitabine and intravenous 5-fluorouracil (5-FU) are both used as a radiosensitizer in chemoradiotherapy (CRT). A capecitabine-based regimen is more convenient for both patients and healthcare professionals. Since large comparative studies are lacking, we compared toxicity, overall survival (OS) and disease-free survival (DFS) between both CRT-regimens in patients with muscle-invasive bladder cancer (MIBC).
Seed-displacements in the immediate post-implant phase in permanent prostate brachytherapy
Andre Karius a,b,⇑, Claudia Schweizer a,b , Vratislav Strnad a,b , Michael Lotter a,b , Stephan Kreppner a,b , Allison Lamrani a,b , Rainer Fietkau a,b , Christoph Bert a,b
doi : 10.1016/j.radonc.2023.109590
Volume 183, June 2023, 109590
To investigate differences in seed-displacements between the immediate post-implant phase (day 0–1) and the time to post-plan computed tomography (CT) (day 1–30) in seed prostate brachytherapy.
Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study
Chad Tang a,⇑, Jeremiah Sanders a , Howard Thames a , David M Swanson a , Juanita M. Crook b , Teresa Bruno a , Pierre Blanchard c , Jay Ciezki d , Mira Keyes b , Daniel Song e , Tanmay Singh e , Gregory Merrick f , Richard Stock g , Francis J. Sullivan h , Henry Mok a , Jeremy Millar i , Steven J. Frank a
doi : 10.1016/j.radonc.2023.109599
Volume 183, June 2023, 109599
Pd-103 and I-125 are commonly used in low dose rate (LDR) brachytherapy for prostate cancer. Comparisons of outcomes by isotope type are limited, but Pd-103 has distinct radiobiologic advantages over I-125 despite its lesser availability outside the United States. We evaluated oncologic outcomes after Pd-103 vs I-125 LDR monotherapy for prostate cancer.
Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients
Marcin Miszczyk a,b,⇑, �ukasz Magrowski a , Tomasz Krzysztofiak c , Rafał Stando d , Wojciech Majewski e , Konrad Stawiski f , Oliwia Masri a , Jakub Ciepał a , Gabriela Depowska a , Krystyna Chimiak a , Gabriela Bylica a , Barbara Czapla a , Małgorzata Masri a , Franciszek Cichur a , Iwona Jabłon � ska a , Marta Gmerek a , Zuzanna Nowicka f , Piotr Wojcieszek c , Jacek Sadowski d , Rafał Suwin � ski g , Paweł Rajwa h,i , Gregor Goldner b , Matthias Moll
doi : 10.1016/j.radonc.2023.109632
Volume 183, June 2023, 109632
Despite several prospective trials showing a clinical benefit of combining external beam radiotherapy (EBRT) with brachytherapy boost (BTB) for the treatment of intermediate- and high-risk prostate cancer (PCa) patients, none of these trials was designed to test for a survival difference.
Advances in radiotherapy and its impact on second primary cancer risk: A multi-center cohort study in prostate cancer patients
Marie-Christina Jahreiß a , Mischa Hoogeman a , Katja KH Aben b,c , Maarten Dirkx a , Renier Snieders b , Floris J Pos d , Tomas Janssen d , Andre Dekker e , Ben Vanneste e,f , Andre Minken g , Carel Hoekstra g , Robert J Smeenk h , Luca Incrocci a , Wilma D Heemsbergen
doi : 10.1016/j.radonc.2023.109659
Volume 183, June 2023, 109659
Modelling studies suggest that advanced intensity-modulated radiotherapy may increase second primary cancer (SPC) risks, due to increased radiation exposure of tissues located outside the treatment fields. In the current study we investigated the association between SPC risks and characteristics of applied external beam radiotherapy (EBRT) protocols for localized prostate cancer (PCa).
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
Jiaqi Fan a , Anne Adams b , Noëlle Sieg c,d,l , Jan-Michel Heger c,d,l , Philipp Gödel c,d,l , Nadine Kutsch c,d,l , David Kaul e , Marcel Teichert f , Bastian von Tresckow f , Veit Bücklein g , Gretha Goesmann h , Minglun Li h , Nathalie Struve a , Maike Trommer d,i , Philipp Linde a , Johannes Rosenbrock a , Eren Celik a , Olaf Penack j , Martin Stuschke k , Marion Subklewe g , Claus Belka h , Michael von Bergwelt-Baildon g , Peter Borchmann c,d,l , Simone Marnitz a , Christian Baues
doi : 10.1016/j.radonc.2023.109580
Volume 183, June 2023, 109580
Chimeric antigen receptor (CAR) T-cell therapy has improved the limited overall survival (OS) of patients with intensively pretreated diffuse large B-cell lymphoma (DLBCL). However, the potentially life-threatening toxicities of CAR T-cells and early relapses remain a challenge. As suggested by smaller monocentric analyses, radiotherapy (RT) in combination with CAR T-cells may have an immunomodulatory effect.
Clinical outcomes and toxicities of 100 patients treated with proton therapy for chordoma on the proton collaborative group prospective registry
Arpit M. Chhabra a,m,⇑,1 , Stephanie R. Rice j,1 , Adam Holtzman b , J. Isabelle Choi a,k , Shaakir Hasan a,l , Robert H. Press n , John Chang c , Lia Halasz d , Henry K. Tsai e , Chiachien Jake Wang f , Peyman Kabolizadeh g , Vinai Gondi h , William F. Hartsell h , Sujay A. Vora i , Carlos E. Vargas i , Charles B. Simone II
doi : 10.1016/j.radonc.2023.109551
Volume 183, June 2023, 109551
We present efficacy and toxicity outcomes among patients with chordoma treated on the Proton Collaborative Group prospective registry.
Plan quality association between dummy run and individual case review in a prospective multi-institutional clinical trial of postoperative cervical cancer patients treated with intensity-modulated radiotherapy: Japan clinical Oncology Group study (JCOG1402)
Hiroyuki Okamoto a , Naoya Murakami b,c,⇑, Fumiaki Isohashi d , Takahiro Kasamatsu e , Yoko Hasumi f , Hiroaki Kobayashi g , Masayori Ishikawa h , Mitsuhiro Nakamura i , Teiji Nishio j , Hiroshi Igaki b , Satoshi Ishikura k , Nobuo Yaegashi l , Takashi Mizowaki m , Yasumasa Nishimura n , Takafumi Toita
doi : 10.1016/j.radonc.2023.109630
Volume 183, June 2023, 109630
The Japan Clinical Oncology Group (JCOG) 1402 conducted a multicenter clinical trial of postoperative intensity-modulated radiotherapy (IMRT) for high-risk uterine cervical cancer patients. We assess effectiveness of the quality assurance (QA) program in central review through dummy runs (DRs) performed before patient enrollment and post-treatment individual case review (ICR), and clarify the pitfalls in treatment planning.
Inguinal nodal clinical target volume delineation based on analysis of anatomical locations of normal and metastatic lymph nodes in pelvic malignant tumors
Yu Chang a,b,1 , Guilin Li a,b,1 , Zhiyong Yang a,b,1 , Guang Han c , Xiangpan Li d , Ye Zhao a,b , Qin Yang a,b , Gang Wu a,b , Kunyu Yang a,b,⇑, Yingchao Zhao
doi : 10.1016/j.radonc.2023.109634
Volume 183, June 2023, 109634
To optimize inguinal nodal clinical target volume (CTV) delineation based on analysis of the anatomical locations and embryonic development of normal and metastatic inguinal lymph nodes (ILNs) in patients with pelvic malignant tumors, including cervical, vaginal, vulvar, and anal tumors.
ESGO/ESTRO quality indicators for radiation therapy of cervical cancer
Cyrus Chargari a,⇑, Kari Tanderup b , François Planchamp c , Luis Chiva d , Pauline Humphrey e , Alina Sturdza f , Li T Tan g , Elzbieta van der Steen-Banasik h , Ignacio Zapardiel i , Remi A Nout j , Christina Fotopoulou
doi : 10.1016/j.radonc.2023.109589
Volume 183, June 2023, 109589
The European Society of Gynaecological Oncology (ESGO) has previously defined and established a list of quality indicators for the surgical treatment of cervical cancer. As a continuation of this effort to improve overall quality of care for cervical cancer patients across all aspects, ESGO and the European SocieTy for Radiotherapy and Oncology (ESTRO) initiated the development of quality indicators for radiation therapy of cervical cancer.
Radiotherapy for mediastinal lymphoma in breath hold using surface monitoring and nasal high flow oxygen: Clinical experiences and breath hold stability
Richard Canters ⇑, Femke Vaassen, Indra Lubken, Maud Cobben, Lars Murrer, Stephanie Peeters, Maaike Berbee, Bastiaan Ta
doi : 10.1016/j.radonc.2023.109594
Volume 183, June 2023, 109594
In this study we describe the clinical introduction and evaluation of radiotherapy in mediastinal lymphoma in breath hold using surface monitoring combined with nasal high flow therapy (NHFT) to prolong breath hold duration.
The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trial
John Nikitas a , Lauren M. Smith a , Yu Gao a , Ting Martin Ma a , Ankush Sachdeva a , Stephanie M. Yoon a , Tommy Jiang a , Daniel A. Low a , Leslie K. Ballas b , Michael L. Steinberg a , Minsong Cao a , Amar U. Kishan
doi : 10.1016/j.radonc.2023.109631
Volume 183, June 2023, 109631
We examined the interfractional variations of clinical target volumes (CTVs), planning target volumes (PTVs), and organs-at-risk (OARs) in patients receiving MRI-guided stereotactic body radiotherapy (SBRT) to the prostate bed and evaluated the potential role of adaptive planning.
Influence of the irradiated pulmonary microenvironment on macrophage and T cell dynamics
Angela M Groves a,⇑,1 , Ravi Misra b,1 , Geremy Clair c , Eric Hernady a , Heather Olson c , Danny Orton c , Jacob Finkelstein b , Brian Marples a , Carl J Johnston
doi : 10.1016/j.radonc.2023.109543
Volume 183, June 2023, 109543
The lung is sensitive to radiation, increasing normal tissue toxicity risks following radiation therapy. Adverse outcomes include pneumonitis and pulmonary fibrosis, which result from dysregulated intercellular communication within the pulmonary microenvironment. Although macrophages are implicated in these pathogenic outcomes, the impact of their microenvironment is not well understood.
Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models
Chiara Valentini a,⇑, Nadja Ebert a,b,c , Lydia Koi a,c,d , Manuel Pfeifer e , Steffen Löck a,c,f , Christoph Erdmann c , Mechthild Krause a,c,d,f,g,h,i , Michael Baumann
doi : 10.1016/j.radonc.2023.109546
Volume 183, June 2023, 109546
To perform a preclinical trial comparing the efficacy of fractionated radiotherapy versus radiochemotherapy with cisplatin in HPV-positive and negative human head and neck squamous cell carcinoma (HNSCC) xenografts.
Machine-learning with region-level radiomic and dosimetric features for predicting radiotherapy-induced rectal toxicities in prostate cancer patients
Zhuolin Yang a,b,⇑, David J. Noble c,d , Leila Shelley a , Thomas Berger a , Raj Jena e , Duncan B. McLaren c,d , Neil G. Burnet f , William H. Nailon
doi : 10.1016/j.radonc.2023.109593
Volume 183, June 2023, 109593
This study aims to build machine learning models to predict radiation-induced rectal toxicities for three clinical endpoints and explore whether the inclusion of radiomic features calculated on radiotherapy planning computerised tomography (CT) scans combined with dosimetric features can enhance the prediction performance.
Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patients
Alessandro Cicchetti a,b,⇑, Claudio Fiorino c , Martin A. Ebert d,e,f , Jacopo Iacovacci a,b , Angel Kennedy e , David J. Joseph d,f,g , James W. Denham h , Vittorio Vavassori i , Gianni Fellin j , Cesare Cozzarini k , Claudio Degli Esposti l , Pietro Gabriele m , Fernando Munoz n , Barbara Avuzzi o , Riccardo Valdagni a,o,p,1 , Tiziana Rancati
doi : 10.1016/j.radonc.2023.109628
Volume 183, June 2023, 109628
To validate published models for the risk estimate of grade ≥ 1 (G1+), grade ≥ 2 (G2+) and grade = 3 (G3) late rectal bleeding (LRB) after radical radiotherapy for prostate cancer in a large pooled population from three prospective trials.
Prognosis prediction for glioblastoma multiforme patients using machine learning approaches: Development of the clinically applicable model
Yeseul Kim a,1 , Kyung Hwan Kim b,1 , Junyoung Park c , Hong In Yoon b,⇑, Wonmo Sung
doi : 10.1016/j.radonc.2023.109617
Volume 183, June 2023, 109617
Protocol letter: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study (InGReS) – A Phase 1 multicentre feasibility study
Delali Adjogatse a,b,⇑, Andriana Michaelidou a,b , Beatriz Sanchez Nieto c , Robert Kozarski a , Isabel Sassoon d , Mererid Evans e , Thomas Rackley e , Simon Shah f , David Eaton a,f , Lucy Pike a , Sorcha Curry g , Sarah-May Gould g , Christopher Thomas a,f , Anthony Kong b , Imran Petkar b , Miguel Reis-Ferreira b , Stephen Connor a,h,i , Sally Fiona Barrington a,g , Mary Lei b , Teresa Guerrero Urbano
doi : 10.1016/j.radonc.2023.109645
Volume 183, June 2023, 109645
Methodological concerns for ultra-hypofractionated neoadjuvant radiation therapy in soft tissue sarcoma
Shu-Wei HsuYung-Shuo Kao
doi : 10.1016/j.radonc.2023.109596
Volume 183, June 2023, 109596
Radiotherapy innovation in rare diseases-focusing on the value of single institutional experiences for hypofractionated radiotherapy in soft tissue sarcoma
Zachary S. MayoNathan MeskoLukas NystromChirag S. ShahJacob G. ScottShauna R. Campbell
doi : 10.1016/j.radonc.2023.109626
Volume 183, June 2023, 109626
Corrigendum to “Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens� [Radiother. Oncol. 137 (2019) 24–31]
Sarah Meneceur a,b , Steffen Löck a,c,d,e , Volker Gudziol f , Sandra Hering g , Rebecca Bütof a,e,h , Maximilian Rehm a,e,h , Michael Baumann a,b,c,d,e,h , Mechthild Krause a,b,c,d,e,h , Cläre von Neubeck
doi : 10.1016/j.radonc.2023.109619
Volume 183, June 2023, 109619
